Ascentage Pharma presents preclinical combination-therapy studies at AACR 2026 annual meeting

• Ascentage Pharma outlined four preclinical combination-therapy studies slated for poster presentation at AACR 2026 in San Diego, running April 17-22.
• Olverembatinib showed antitumor activity in endometrial carcinoma models, with combination treatment strengthening effects versus standard chemotherapy in preclinical testing.
• Separate mantle cell lymphoma work indicated olverembatinib could enhance responses when paired with acalabrutinib, supporting a potential new combination strategy beyond its China-approved CML use.
• APG-2449 data suggested it could help counter resistance to standard MAPK-pathway blockade in BRAF V600E-mutant tumor models, pointing to a potential development path in melanoma or colorectal cancer.
• APG-5918 results indicated it could restore chemosensitivity in small-cell lung cancer models when combined with topoisomerase I inhibitors, supporting a future clinical-combination approach.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604192000PRIMZONEFULLFEED9692417) on April 20, 2026, and is solely responsible for the information contained therein.